Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Grifols' AMBAR Clinical Trial Published in Alzheimer's & Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Grifols International"}]

Grifols International

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Results of Grifols' AMBAR Clinical Trial Published in Alzheimer's & Dementia

Details:

Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.

Lead Product(s): Perflutren,Immunoglobulin G 285-292

Therapeutic Area: Neurology Product Name: Albutein

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY